Professional
Added to YB: 2024-08-21
Pitch date: 2024-06-30
RCKT [bullish]
Rocket Pharmaceuticals, Inc.
-83.79%
current return
Author Info
No bio for this author
Company Info
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Market Cap
$523.3M
Pitch Price
$21.34
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.66
P/E
-2.40
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Baron Health Care Fund Portfolio Holding: Rocket Pharmaceuticals, Inc.
RCKT: Gene therapy co for rare diseases. 3 drugs launching by 2025. FDA extended review for Kresladi (LAD therapy). Stock down on slow gene therapy launches by competitors. High conviction due to lifesaving nature & unmet needs. Pipeline: Danon disease, Fanconi anemia, LAL deficiency, pyruvate kinase deficiency.
Read full article (1 min)